Accelr8 Completes Deal for $35M Investment, New CEO Named | GenomeWeb

NEW YORK (GenomeWeb News) – Accelr8 today announced that it has received shareholder approval, met all closing conditions, and completed a transaction that will bring in a $35 million investment.

The investment, which was announced in April, will go toward the development and commercialization of the company's BACcel culture-free diagnostic system for same-shift identification and antibiotic resistance testing of bacterial and fungal pathogens.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.